Fresenius SE & Co. KGaA
Explore by topic
5-year stock timeline
Fresenius: From Conglomerate Complexity to Therapy-Focused Simplicity
2021: Pandemic Resilience and Strategic Pivot
Fresenius Kabi launched "Vision 2026," a strategic pivot toward Biopharma, Nutrition, and MedTech while sustaining operations through COVID. The Board proposed its 29th consecutive dividend increase to €0.92, emphasizing operational resilience.[16,17]
Investors viewed the company as a defensive healthcare conglomerate with solid cash flow and dividend characteristics, though pandemic uncertainty remained. After early-2021 pressure, the stock improved into late-2021 following better-than-expected Q3 signals and a November guidance uplift.[28]
November 2021: Guidance Uplift
Q3/21 results showed progress on cost efficiencies and volume recovery. Management raised full-year sales and earnings guidance, generating short-term optimism around vaccination and reopening dynamics.[28] The rally proved transient as COVID risks persisted and re-rating remained limited.
August–September 2022: Leadership Shock and Earnings Deterioration
CEO Stephan Sturm announced his departure; Michael Sen was appointed effective October 1, 2022. The announcement coincided with weaker near-term net income guidance, triggering a sharp market sell-off that drove shares to multi-year lows.[2,1]
Perception shifted abruptly toward "execution risk / value trap." The stock experienced pronounced downside through August and September with increased volatility and volume.
December 2022: FMC Governance Turbulence
Carla Kriwet resigned as Fresenius Medical Care CEO; Helen Giza was appointed. This management churn across the group amplified investor concern about structural cohesion and governance.[3,11,1]
FMC—the group's largest cash and earnings contributor—became an additional overhang. Investor focus sharpened on structural simplification and management clarity. Trading remained choppy with intra-period volatility tied to headline risk.
February 2022: Weaker Outlook and Deconsolidation Signal
Fresenius flagged a weaker 2023 earnings outlook and announced a strategic change: the legal form of Fresenius Medical Care would shift toward deconsolidation, ceding strategic oversight.[4,14]
Two competing narratives emerged: near-term margin pressure from macro headwinds and inflation, versus potential long-term value unlock from simplification. Investors divided between "value trap" and "eventual re-rating" camps. The stock experienced a large sell-off followed by volatile consolidation.
July 2023: Deconsolidation Approved
An Extraordinary General Meeting saw Fresenius Medical Care shareholders overwhelmingly approve (≳99%) conversion from KGaA to AG—a decisive step toward deconsolidation and structural simplification.[14]
The simplification narrative strengthened. Many investors shifted from viewing the company as a conglomerate-discounted holding toward valuing Helios and Kabi more distinctly. The stock rallied on clarity, then retraced as markets awaited implementation details and P&L impact.
August 2023: VAMED Restructuring and Write-Downs
Q2/23 results disclosed sizable VAMED restructuring charges: approximately €332m in Q2 write-downs and provisions, with an additional €200–250m anticipated. Management stated that going forward, FY guidance would exclude Fresenius Medical Care.[14]
Simplification remained credible, but VAMED emerged as a near-term earnings drag. Narrative became "simplify now, absorb short-term pain for clearer long-term margins." The stock declined on the VAMED news, then entered a volatile base as investors digested one-offs.
November 2023: Deconsolidation Formally Registered
The conversion and change in legal form were entered into the commercial register, marking a formal step in implementing the simplification program.[6]
Structural simplification was now formally delivered. Buy-side attention shifted to standalone metrics for Kabi and Helios, and to valuation of the FMC minority stake. Reduced headline uncertainty helped trim a portion of the conglomerate discount. The stock stabilized and began a multi-month recovery as downside volatility abated.
May 2024: VAMED Exit Finalized
Fresenius announced a structured exit from VAMED: sale of Austrian operations to Porr/Strabag for €90m, transfer of HES to Fresenius, and orderly scaling of international project business. The company flagged approximately €0.6bn in non-cash special items and removed VAMED as a reporting segment as of Q2/24.[10]
Investors saw decisive portfolio pruning—removal of a cyclical, project-driven business in exchange for a cleaner, therapy-focused group (Kabi and Helios) with an improved medium-term EBIT/ROIC profile. Narrative evolved toward "simpler, more defensive compounder." The stock rallied on the announcement, absorbed the booked charges, then entered a mid-term uptrend as markets re-rated the group on clearer cash and earnings quality.
2024–2025: Operating Company Execution
Fresenius Kabi progressed with biosimilar launches (tocilizumab approval and EU launch around 2023–24) and MedTech/Nutrition growth. Fresenius Medical Care pursued portfolio optimization through clinic sales and network disposals as post-restructuring housekeeping.[5,8,14]
Growing confidence emerged in recurring earnings from Kabi and Helios. Fresenius increasingly traded as a defensive healthcare operator with a clearer capital-allocation story and fewer structural overhangs. Investor thesis shifted from "complex conglomerate" to "earnings quality and dividend." The stock entered a steadying uptrend with periodic rallies on positive Kabi/Helios results and fewer negative headline surprises.
2025 to July 2026: Simplified Structure and Execution Phase
Corporate governance items and management engagement continued under #FutureFresenius. The group now comprises two Operating Companies (Fresenius Kabi and Fresenius Helios, each 100% owned) and an Investment Company stake (Fresenius Medical Care, approximately 32% ownership) following portfolio actions.[7,9,10]
By mid-2026, perception had settled on a substantially simplified, therapy-focused group. The narrative centered on "defensive compounder / execution-led re-rating" with valuation now sensitive to net-debt trajectory and margin delivery. The stock stabilized and recovered gradually to €43.41 as of July 7, 2026, reflecting the full arc: pandemic volatility, 2022 leadership and earnings shock, 2023 simplification turbulence and base formation, and 2024–mid-2026 recovery as simplification executed and operating companies delivered.
Key risks and downside factors
Fresenius SE & Co. KGaA operates a diversified global healthcare portfolio spanning hospital operations through Helios, hospital products and IV/generic medicines alongside clinical nutrition via Fresenius Kabi, and a meaningful stake in renal care. The competitive landscape includes global medtech and pharmaceutical suppliers, large dialysis operators, and regional hospital networks. The business faces structural headwinds: regulatory and reimbursement shifts, relentless price pressure in commoditized hospital products and injectables, and the capital intensity of running hospital operations. Material risks center on reimbursement and regulatory changes, competitive margin erosion, supply chain and quality vulnerabilities in sterile manufacturing, and the leverage and operational complications that arise from hospital acquisitions and rising labor costs.
- Hospital reimbursement and regulatory risk: reforms to diagnosis-related group pricing or reductions in public funding across Germany, Spain, and other key markets pose material downside to Helios revenues and margins.
- Pricing pressure and intensifying competition across IV generics, clinical nutrition, and biosimilars pose a real risk to Fresenius Kabi's margins and market position. Low-cost competitors and the steady commoditization of these categories could erode share relative to better-positioned peers like Baxter and the larger generics manufacturers.
- Hospital operations carry structural vulnerabilities that compound during stress. High fixed costs mean occupancy swings hit profitability disproportionately hard—a bed sitting empty doesn't reduce much overhead. M&A integration, common in the sector, introduces execution risk alongside the financial leverage taken on to fund deals. Layer in wage inflation, particularly acute in healthcare labor markets, and you're looking at margin compression that's difficult to pass through to payers. The combination leaves operators exposed: capital intensity locks in commitments, integration demands management bandwidth, and labor costs move independently of revenue. It's a setup where operational discipline matters more than in most industries.
- Supply chain disruptions, manufacturing defects, and regulatory lapses in sterile injectables and medical devices carry material consequences: production halts, contamination events, product recalls, and enforcement actions from regulators can erode revenue and credibility alike.
Competitive landscape
Fresenius operates across three interconnected healthcare domains: hospital operations through Helios, hospital products and IV therapies alongside biosimilars via Kabi, and a material stake in dialysis through Fresenius Medical Care. This structure positions the company against a fragmented competitive landscape—global medtech players, generic and biosimilar manufacturers, standalone dialysis operators, and large private hospital networks spanning Europe and the US. The business carries genuine structural pressures. Reimbursement and regulatory headwinds compress hospital margins. Generics and biosimilars face relentless price competition, as do infusion products. Labor and supply costs continue climbing. Beyond operations, the company navigates financial and legal complications tied to ongoing divestments, foreign exchange exposure, and financing covenants that narrow flexibility. Sources: Fresenius 2025 Annual Report; FinancialReports.eu; AssetNext.
| Company | Ticker |
|---|---|
| Fresenius Medical Care AG & Co. KGaA | FME.XETRA |
| Baxter International Inc. | BAX.NYSE |
| DaVita Inc. | DVA.NYSE |
| HCA Healthcare, Inc. | HCA.NYSE |
Private competitors
- B. Braun Melsungen AG
- Asklepios Kliniken
- Sana Kliniken
- Vithas (Grupo Vithas)
Get More Stock Analyses Like This
Receive hand-picked stock recommendations with detailed analyses every week
Start Free TrialPerformance Figures of Fresenius SE & Co. KGaA
Relative Performance vs Benchmarks
| Period | Fresenius SE & Co. KGaA | vs DAX | vs S&P 500 (SPY) |
|---|---|---|---|
| 1M | +17.58% | +15.87% | +16.17% |
| 3M | +0.27% | -4.90% | -9.99% |
| 6M | -9.37% | -8.49% | -17.67% |
| 1Y | +6.26% | +2.83% | -15.61% |
| 3Y | +85.38% | +24.91% | +8.40% |
| 5Y | +9.10% | -50.50% | -74.59% |
Get More Stock Analyses Like This
Receive hand-picked stock recommendations with detailed analyses every week
Start Free TrialHistorical valuation trends
How the company’s key valuation ratios (P/E, P/S, P/B and P/CF) have evolved over time compared to today.
| Period | P/E Ratio | P/S Ratio | P/B Ratio | P/CF Ratio |
|---|---|---|---|---|
| Current | 16.6 | 1.1 | 1.2 | 8.3 |
| 1Y ago | 21.5 | 1.1 | 1.3 | 10.9 |
| 3Y ago | 13.7 | 0.3 | 0.7 | 3.1 |
| 5Y ago | 14.1 | 0.7 | 1.4 | 5.3 |
Frequently Asked Questions
Where is the Fresenius SE & Co. KGaA stock traded?
What does Fresenius SE & Co. KGaA do?
What are the key metrics for FRE.XETRA?
How has Fresenius SE & Co. KGaA's stock price performed?
How is FRE.XETRA valued?
Does FRE.XETRA pay dividends?
What are the key risks when investing in FRE.XETRA?
- Hospital reimbursement and regulatory risk: reforms to diagnosis-related group pricing or reductions in public funding across Germany, Spain, and other key markets pose material downside to Helios revenues and margins.
- Pricing pressure and intensifying competition across IV generics, clinical nutrition, and biosimilars pose a real risk to Fresenius Kabi's margins and market position. Low-cost competitors and the steady commoditization of these categories could erode share relative to better-positioned peers like Baxter and the larger generics manufacturers.
- Hospital operations carry structural vulnerabilities that compound during stress. High fixed costs mean occupancy swings hit profitability disproportionately hard—a bed sitting empty doesn't reduce much overhead. M&A integration, common in the sector, introduces execution risk alongside the financial leverage taken on to fund deals. Layer in wage inflation, particularly acute in healthcare labor markets, and you're looking at margin compression that's difficult to pass through to payers. The combination leaves operators exposed: capital intensity locks in commitments, integration demands management bandwidth, and labor costs move independently of revenue. It's a setup where operational discipline matters more than in most industries.
- Supply chain disruptions, manufacturing defects, and regulatory lapses in sterile injectables and medical devices carry material consequences: production halts, contamination events, product recalls, and enforcement actions from regulators can erode revenue and credibility alike.
Who are the main competitors of Fresenius SE & Co. KGaA?
- Fresenius Medical Care AG & Co. KGaA (FME.XETRA)
- Baxter International Inc. (BAX.NYSE)
- DaVita Inc. (DVA.NYSE)
- HCA Healthcare, Inc. (HCA.NYSE)
When does Fresenius SE & Co. KGaA report earnings?
Key Metrics
Valuation Metrics
Profitability Metrics
Growth Metrics
Dividend history
Long-term record of paid dividends (amount per share and dividend yield at the time of payment).
| Year | Dividend | Yield at payment | Avg. yield |
|---|---|---|---|
| 2026 | 1.05 EUR | 2.71% | 1.8% |
| 2025 | 1.00 EUR | 2.32% | |
| 2023 | 0.92 EUR | 3.33% | |
| 2022 | 0.92 EUR | 2.70% | |
| 2021 | 0.88 EUR | — | |
| 2020 | 0.84 EUR | 2.13% | |
| 2020 | 0.84 EUR | 1.88% | |
| 2019 | 0.80 EUR | 1.64% | |
| 2018 | 0.75 EUR | — | |
| 2017 | 0.62 EUR | 0.78% | |
| 2016 | 0.55 EUR | — | |
| 2015 | 0.38 EUR | 0.67% | |
| 2014 | 0.42 EUR | 1.12% | |
| 2013 | 0.37 EUR | 1.14% | |
| 2012 | 0.32 EUR | 1.22% |
Earnings history & estimates
Historical earnings performance shows how consistently the company meets or exceeds analyst expectations. Forward estimates provide insight into expected profitability and growth trajectory.
Historical earnings performance
Upcoming earnings report
Analyst estimates for upcoming periods
Key financial figures
Selected income statement, balance sheet and cash flow figures. Annual and quarterly, based on reported IFRS/GAAP financials.
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | 22.87B | 21.83B | 21.07B | 21.33B | 37.08B |
| Operating income (EBIT) | 2.50B | 1.84B | 1.29B | 2.00B | 3.60B |
| Net income | 1.26B | 471.00M | -594.00M | 1.37B | 1.82B |
| Free cash flow | 1.20B | 1.52B | 3.32B | 2.28B | 3.03B |
| Total assets | 41.40B | 43.55B | 45.28B | 76.42B | 71.96B |
| Equity | 19.10B | 19.54B | 19.00B | 20.41B | 19.00B |
| Net debt | 10.35B | 11.53B | 13.27B | 25.59B | 24.55B |
PWP Leeway UG (haftungsbeschränkt)
